Cardiovascular: Heart failure, heart block, bradycardia, hypotension, dizziness, peripheral vasoconstriction with coldness of the extremities (including exacerbation of intermittent claudication and Raynaud’s phenomenon). (see 4.4, Special Warnings and Precautions for Use).
Eye : Visual disturbances including blurred vision, sore eyes, dry eyes (reversible on withdrawal; discontinuance of the drug should be considered if any such reaction is not otherwise explicable), conjunctivitis.
Gastrointestinal: Nausea, vomiting, diarrhoea, constipation and abdominal cramps, sclerosing peritonitis and retroperitoneal fibrosis.
General: Fatigue, headache, dry mouth, sleep disturbances of the type noted with other beta-blockers have been reported rarely. An increase in (A)nti (N)uclear (A)ntibodies has been seen: its clinical relevance is not clear.
Haemopoietic: Thrombocytopenia, eosinophilia and leucopenia including agranulocytosis.
Hepatic: Elevated liver enzymes and/or bilirubin
Metabolic: Lupus-like syndrome. Hyperglycaemia or hypoglycaemia. Non-diabetic patients susceptible to hypoglycaemia include those on regular dialysis, and long term patients who are nutritionally compromised or have liver disease. Atenolol may increase serum triglyceride levels.
Musculoskeletal, connective tissue and bone disorders: Myopathies including muscle cramps, arthralgia.
Nervous system: Paraesthesia, peripheral neuritis.
Psychiatric: Depression, psychosis, hallucinations, confusion, anxiety and nervousness.
Respiratory : Bronchospasm, pneumonitis, pulmonary fibrosis and pleurisy.
Reproductive: Impotence, Peyronie’s disease;
Skin: Purpura, pruritus, reversible alopecia, skin rashes (reversible on withdrawal; discontinuance of the drug should be considered if any such reaction is not otherwise explicable), psoriasiform rash or exacerbation of psoriasis